Revenio Q1'26 preview: Visionix elevates Revenio to the big leagues

Translation: Original published in Finnish on 4/24/2026 at 8:30 am EEST.

Revenio will publish its Q1 report on April 28, 2026, but investors' attention is focused on the Visionix acquisition (purchase price 290 MEUR, EV). Visionix elevates Revenio to the big leagues, but before that, a challenging 18-month integration period lies ahead. We have updated our estimates to reflect the new entity forming this summer, which has required several uncertain assumptions. We reiterate our Buy recommendation for Revenio, as the combined company's long-term earnings potential is attractive, and the valuation is very reasonable in relation to this. However, in the short term, the arrangement involves a lot of uncertainty, and we have lowered our target price to EUR 20.0 (was EUR 24.0).

A strategically missing piece falls into place

Visionix brings Revenio a long-missing OCT and OCT-A portfolio, as well as a broader offering of diagnostics, refraction, and lens finishing solutions (e.g. Optovue, Briot, Weco). The company's total addressable market (TAM) will increase by ~2.5 times to 2.5 BUSD, and the combined company's offering will cover most of the ophthalmic diagnostics value chain. Strategically, we consider the companies' compatibility excellent, and in our assessment, Visionix's products and technology are competitive. Strategically, we consider the companies' compatibility excellent, and in our assessment, Visionix's products and technology are competitive. We are particularly confident in the company's OCT expertise, where Visionix has been a pioneer, especially in OCT-A solutions. We estimate current OCT revenue to be over 35 MEUR annually. In our assessment, Visionix holds around a 5% market share in the attractive OCT market, but there is potential for significantly higher growth.

Synergies and integration determine success

Integrating Visionix into our figures has required several assumptions, which contain significant uncertainty. Nevertheless, we believe the outline provides investors with a better picture of the future and offers added value. For Visionix, we estimate that the company's profitability will increase by 3 percentage points due to the already ongoing program in 2027, which would bring the EBITDA margin to 14.6%. We have cut old Revenio’s organic growth forecast from 11% to 7% (CAGR 2026-29e), as critical integration ties up management and organizational attention. The company targets over 20 MEUR in synergies by 2029 and an EBITDA margin of 25% in 2028-29. Our forecasts support achieving the 25% level, although we consider our synergy estimates (12 MEUR 2028e / 14 MEUR 2030e) to be more conservative than the company's own target. We are confident in the cost synergies that are already well-planned according to our assessment, but we are very cautious regarding sales synergies.

Expected return attractive when looking beyond integration period

It is difficult for us to estimate an acceptable valuation for the combined company, but we expect it to reach Revenio's pre-transaction level. Revenio was clearly among the winners in its niche areas, and the company's profitability was excellent, but we believe the combined company's growth profile, market position, and resources will be significantly stronger than before. Looking beyond the challenging integration period to 2028, the stock's EV/EBIT is 10x based on our forecasts. We see an upside of approximately 50% over a two-year period, assuming a "neutral" valuation level of EV/EBIT 15x. Before this, however, there will be an estimated 18-month integration period, which the company must successfully navigate. New PPA depreciations (estimated 6 MEUR/year) and integration costs (20 MEUR) will weigh on reported earnings, especially in 2026-2027, which will require patience from investors to look beyond the immediate developments. In addition, the arrangement significantly increases Revenio's indebtedness, exposes the company to interest rate risk in the coming years, and increases the number of shares by an estimated 32% in future offerings (includes significant assumptions). Currently, there is also no guidance, which causes additional uncertainty. Despite all of this, we estimate that taking risks is currently worthwhile.